Kai Wiechen

1.6k total citations · 1 hit paper
22 papers, 1.2k citations indexed

About

Kai Wiechen is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Kai Wiechen has authored 22 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 10 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Oncology. Recurrent topics in Kai Wiechen's work include Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (6 papers) and Glycosylation and Glycoproteins Research (4 papers). Kai Wiechen is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), HER2/EGFR in Cancer Research (6 papers) and Glycosylation and Glycoproteins Research (4 papers). Kai Wiechen collaborates with scholars based in Germany, United States and Ukraine. Kai Wiechen's co-authors include Manfred Dietel, Christine Sers, Alexander I. Agoulnik, Bakhyt Zhumabayeva, Reinhold Schäfer, Stefan Herzig, Luda Diatchenko, Martin Schüler, Karl Dhaene and Daniel Maurus and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Physiology and Oncogene.

In The Last Decade

Kai Wiechen

22 papers receiving 1.2k citations

Hit Papers

FAST: a randomised phase II study of zolbetuximab (IMAB36... 2021 2026 2022 2024 2021 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
    2021 244 citations Uğur Şahin, Ö. Türeci et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kai Wiechen Germany 14 533 378 337 284 226 22 1.2k
Laura Gualandi Sweden 9 966 1.8× 152 0.4× 326 1.0× 91 0.3× 245 1.1× 14 1.3k
Nathan V. Lee United States 14 673 1.3× 150 0.4× 459 1.4× 326 1.1× 312 1.4× 23 1.2k
Salahaldin A. Tahir United States 20 900 1.7× 967 2.6× 526 1.6× 375 1.3× 533 2.4× 26 1.9k
Cathy Maass Netherlands 15 440 0.8× 98 0.3× 186 0.6× 147 0.5× 228 1.0× 24 995
Clara Tan Canada 8 1.2k 2.3× 415 1.1× 292 0.9× 68 0.2× 262 1.2× 8 1.7k
Beverly L. Falcón United States 16 804 1.5× 68 0.2× 435 1.3× 216 0.8× 339 1.5× 34 1.4k
Ayush Dagvadorj United States 19 672 1.3× 243 0.6× 448 1.3× 270 1.0× 206 0.9× 23 1.2k
Sarah Beck Germany 16 534 1.0× 63 0.2× 203 0.6× 199 0.7× 89 0.4× 30 1.0k
Habib Boukerche France 20 809 1.5× 309 0.8× 504 1.5× 85 0.3× 196 0.9× 33 1.6k
Tanguy Lechertier United Kingdom 15 630 1.2× 196 0.5× 261 0.8× 64 0.2× 239 1.1× 17 1.1k

Countries citing papers authored by Kai Wiechen

Since Specialization
Citations

This map shows the geographic impact of Kai Wiechen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai Wiechen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai Wiechen more than expected).

Fields of papers citing papers by Kai Wiechen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kai Wiechen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai Wiechen. The network helps show where Kai Wiechen may publish in the future.

Co-authorship network of co-authors of Kai Wiechen

This figure shows the co-authorship network connecting the top 25 collaborators of Kai Wiechen. A scholar is included among the top collaborators of Kai Wiechen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kai Wiechen. Kai Wiechen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Şahin, Uğur, Ö. Türeci, Georgy M. Manikhas, et al.. (2021). FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Annals of Oncology. 32(5). 609–619. 244 indexed citations breakdown →
2.
Türeci, Ö., Uğur Şahin, Henning Schulze‐Bergkamen, et al.. (2019). A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Annals of Oncology. 30(9). 1487–1495. 161 indexed citations
3.
Şahin, Uğur, Özlem Türeci, Georgy M. Manikhas, et al.. (2019). Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial.. Journal of Clinical Oncology. 37(4_suppl). 16–16. 16 indexed citations
4.
Althoff, Christian E., Kay‐Geert Hermann, Kai Wiechen, et al.. (2006). Formalin-fixed Blood Clots-Additional Histological Findings on Computed Tomography-guided Fine-Needle Aspiration Biopsies in Comparison with Core Biopsies. Journal of Computer Assisted Tomography. 30(3). 386–390. 5 indexed citations
5.
Noske, Aurelia, Carsten Denkert, Christine Sers, et al.. (2005). Loss of Gelsolin expression in human ovarian carcinomas. European Journal of Cancer. 41(3). 461–469. 69 indexed citations
6.
Anagnostopoulos, I, Kai Wiechen, H Stein, et al.. (2004). Discordant results obtained for different methods of HER-2/neu testing in breast cancer a question of standardization, automation and timing. The International Journal of Biological Markers. 19(1). 1–13. 19 indexed citations
7.
Lüftner, Diana, I Anagnostopoulos, Kai Wiechen, et al.. (2004). Discordant Results Obtained for Different Methods of HER-2/Neu Testing in Breast Cancer – A Question of Standardization, Automation and Timing. The International Journal of Biological Markers. 19(1). 1–13. 13 indexed citations
8.
Wiechen, Kai. (2003). c- erbB-2 Antisense Oligonucleotides Inhibit Serum-Induced Cell Spreading of Ovarian Cancer Cells. Humana Press eBooks. 39. 769–774. 2 indexed citations
9.
Sers, Christine, Oleg Tchernitsa, Johannes Zuber, et al.. (2002). Gene expression profiling in RAS oncogene-transformed cell lines and in solid tumors using subtractive suppression hybridization and cDNA arrays. Advances in Enzyme Regulation. 42. 63–82. 16 indexed citations
10.
Sers, Christine, Knut Husmann, Irina Nazarenko, et al.. (2002). The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNγ-induced cell death in human ovarian carcinoma cells. Oncogene. 21(18). 2829–2839. 40 indexed citations
11.
Wiechen, Kai, Christine Sers, Alexander I. Agoulnik, et al.. (2001). Down-Regulation of Caveolin-1, a Candidate Tumor Suppressor Gene, in Sarcomas. American Journal Of Pathology. 158(3). 833–839. 148 indexed citations
12.
Wille, Andreas, et al.. (2001). Diagnostic difficulties before definitive treatment of an extragonadal retroperitoneal germ cell tumor. Urology. 58(2). 281–281. 5 indexed citations
13.
Wiechen, Kai, Luda Diatchenko, Alexander I. Agoulnik, et al.. (2001). Caveolin-1 Is Down-Regulated in Human Ovarian Carcinoma and Acts as a Candidate Tumor Suppressor Gene. American Journal Of Pathology. 159(5). 1635–1643. 237 indexed citations
14.
15.
Wiechen, Kai, Christine L. Zimmer, & Manfred Dietel. (1998). Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein.. PubMed. 5(1). 45–51. 31 indexed citations
16.
Müller, Markus, Manfred Dietel, Andreas Turzynski, & Kai Wiechen. (1998). Antisense phosphorothioate oligodeoxynucleotide down-regulation of the insulin-like growth factor I receptor in ovarian cancer cells. International Journal of Cancer. 77(4). 567–571. 32 indexed citations
17.
18.
Wiechen, Kai, David T. Yue, & Stefan Herzig. (1995). Two distinct functional effects of protein phosphatase inhibitors on guinea‐pig cardiac L‐type Ca2+ channels.. The Journal of Physiology. 484(3). 583–592. 62 indexed citations
19.
Neumann, Joachim, Stefan Herzig, Wilhelm Schmitz, et al.. (1994). Biochemical and electrophysiological mechanisms of the positive inotropic effect of calyculin A, a protein phosphatase inhibitor.. Journal of Pharmacology and Experimental Therapeutics. 271(1). 535–541. 38 indexed citations
20.
Wiechen, Kai, et al.. (1991). Isoelectric focusing pattern of human amniotic fluid α‐fetoprotein. Prenatal Diagnosis. 11(7). 427–435. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Gualandi Breakdown of academic impact, for papers by Nathan V. Lee Breakdown of academic impact, for papers by Salahaldin A. Tahir Breakdown of academic impact, for papers by Cathy Maass Breakdown of academic impact, for papers by Clara Tan Breakdown of academic impact, for papers by Beverly L. Falcón Breakdown of academic impact, for papers by Ayush Dagvadorj Breakdown of academic impact, for papers by Sarah Beck Breakdown of academic impact, for papers by Habib Boukerche Breakdown of academic impact, for papers by Tanguy Lechertier
Rankless by CCL
2026